IMCT-17STATISTICALLY SIGNIFICANT ASSOCIATION OF GLIOBLASTOMA IMMUNOTHERAPY PHASE II CLINICAL STUDY (ICT-107) TREATMENT AND SURVIVAL TO IMMUNE RESPONSE USING A NOVEL COMPREHENSIVE ELISPOT ANALYSIS Article

Santos, Radleigh, Gringeri, Anthony, Yu, John et al. (2015). IMCT-17STATISTICALLY SIGNIFICANT ASSOCIATION OF GLIOBLASTOMA IMMUNOTHERAPY PHASE II CLINICAL STUDY (ICT-107) TREATMENT AND SURVIVAL TO IMMUNE RESPONSE USING A NOVEL COMPREHENSIVE ELISPOT ANALYSIS . NEURO-ONCOLOGY, 17(suppl_5), v111-v111. 10.1093/neuonc/nov218.17

cited authors

  • Santos, Radleigh; Gringeri, Anthony; Yu, John; Janetzki, Sylvia; Judkowski, Valeria; Pinilla, Clemencia

authors

publication date

  • November 1, 2015

published in

keywords

  • 3 Good Health and Well Being
  • 32 Biomedical and Clinical Sciences
  • 3204 Immunology

Digital Object Identifier (DOI)

publisher

  • Oxford University Press (OUP)

start page

  • v111

end page

  • v111

volume

  • 17

issue

  • suppl_5